CN101107010A - 经修饰的链球菌多糖及其用途 - Google Patents

经修饰的链球菌多糖及其用途 Download PDF

Info

Publication number
CN101107010A
CN101107010A CNA2005800440250A CN200580044025A CN101107010A CN 101107010 A CN101107010 A CN 101107010A CN A2005800440250 A CNA2005800440250 A CN A2005800440250A CN 200580044025 A CN200580044025 A CN 200580044025A CN 101107010 A CN101107010 A CN 101107010A
Authority
CN
China
Prior art keywords
polysaccharide
gbs
composition
polypeptide
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800440250A
Other languages
English (en)
Chinese (zh)
Inventor
D·L·卡斯珀
H-K·格特姆森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Publication of CN101107010A publication Critical patent/CN101107010A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
CNA2005800440250A 2004-11-01 2005-11-01 经修饰的链球菌多糖及其用途 Pending CN101107010A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62390704P 2004-11-01 2004-11-01
US60/623,907 2004-11-01

Publications (1)

Publication Number Publication Date
CN101107010A true CN101107010A (zh) 2008-01-16

Family

ID=36319754

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800440250A Pending CN101107010A (zh) 2004-11-01 2005-11-01 经修饰的链球菌多糖及其用途

Country Status (8)

Country Link
US (1) US7858101B2 (enExample)
EP (1) EP1812057A4 (enExample)
JP (1) JP2008518953A (enExample)
CN (1) CN101107010A (enExample)
AU (1) AU2005302269B2 (enExample)
CA (1) CA2586058A1 (enExample)
MX (1) MX2007005202A (enExample)
WO (1) WO2006050341A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0502095D0 (en) * 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
TW200806315A (en) * 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
US9149541B2 (en) 2011-07-08 2015-10-06 Novartis Ag Tyrosine ligation process
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
JP6170932B2 (ja) 2011-11-07 2017-07-26 ノバルティス アーゲー ｓｐｒ００９６抗原およびｓｐｒ２０２１抗原を含むキャリア分子
SG11201500978TA (en) 2012-10-03 2015-07-30 Glaxosmithkline Biolog Sa Immunogenic compositions
GB201300707D0 (en) * 2013-01-15 2013-02-27 Novartis Ag Compounds and processes
CN105593238B (zh) 2013-07-11 2020-09-08 诺华股份有限公司 使用微生物转谷氨酰胺酶进行赖氨酸特异性化学酶法蛋白质修饰
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
EP3638301A1 (en) 2017-06-16 2020-04-22 GlaxoSmithKline Biologicals S.A. Method of treatment
BR112021022429A2 (pt) 2019-05-10 2022-03-22 Glaxosmithkline Biologicals Sa Produção de conjugados
JP2023503086A (ja) 2019-11-22 2023-01-26 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 細菌サッカリド複合糖質ワクチンの用法及び用量
WO2021250626A2 (en) 2020-06-12 2021-12-16 Glaxosmithkline Biologicals Sa Dock tag system

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4207414A (en) 1978-08-16 1980-06-10 President And Fellows Of Harvard College Polysaccharide antigens
US4324887A (en) 1978-08-16 1982-04-13 President And Fellows Of Harvard College Type II group B Streptococci polysaccharide
US4438261A (en) 1980-05-19 1984-03-20 Riker Laboratories, Inc. Anticoagulant substance
US4367222A (en) 1980-06-09 1983-01-04 President And Fellows Of Harvard College Immune globulin specific to Group B streptococci
US4367221A (en) 1980-06-09 1983-01-04 President And Fellows Of Harvard College Immunization against Group B streptococci
US4356263A (en) 1980-06-09 1982-10-26 President And Fellows Of Harvard College Method of making a polysaccharide vaccine
US4367223A (en) 1980-06-09 1983-01-04 President And Fellows Of Harvard College Vaccine against Group B streptococci
US4284537A (en) 1980-07-03 1981-08-18 The United States Of America As Represented By The Department Of Health And Human Services Conjugate of streptococcal M protein peptide vaccine
US4425330A (en) 1981-05-20 1984-01-10 Cornell Research Foundation, Inc. Bovine mastitis vaccine and method for detecting efficacy thereof
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4902506A (en) 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4619828A (en) 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
US4757134A (en) 1982-12-02 1988-07-12 The Rockefeller University IgA binding protein
FR2581877B1 (fr) 1985-05-14 1987-12-18 Louvain Universite Catholique Conjugue constitue d'une adhesine de paroi de s. mutans, de nature proteique et d'un polysaccharide de s. mutans, sa preparation et son utilisation notamment dans des vaccins anti-caries
US5302386A (en) 1986-04-16 1994-04-12 Brigham And Women's Hospital, Inc. Bacterial antigens, antibodies, vaccines and methods of manufacture
US5472696A (en) * 1988-02-26 1995-12-05 Univ. Of Florida Research Foundation, Inc. Antigen of group B streptococci
US5648241A (en) 1989-09-15 1997-07-15 The General Hospital Corporation Conjugate vaccine against group B streptococcus
JP4163251B2 (ja) * 1992-09-24 2008-10-08 ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド グループｂストレプトコッカス・タイプ▲ｉｉ▼およびタイプ▲ｖ▼多糖−蛋白質接合ワクチン
ZA937034B (en) 1992-09-24 1995-06-23 Brigham & Womens Hospital Group B streptococcus type II and type V polysaccharide-protein conjugate vaccines
US6355255B1 (en) 1998-12-07 2002-03-12 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
EP1810978B1 (en) 2000-08-08 2013-02-13 St. Jude Children's Research Hospital Group B streptococcus polypeptides nucleic acids and therapeutic composition and vaccines thereof
AU2003257003A1 (en) 2002-07-30 2004-02-16 Baxter Healthcare S.A. Chimeric multivalent polysaccharide conjugate vaccines

Also Published As

Publication number Publication date
WO2006050341A2 (en) 2006-05-11
WO2006050341A3 (en) 2006-06-15
US7858101B2 (en) 2010-12-28
AU2005302269A1 (en) 2006-05-11
MX2007005202A (es) 2007-07-09
AU2005302269B2 (en) 2011-05-19
EP1812057A2 (en) 2007-08-01
US20060134142A1 (en) 2006-06-22
CA2586058A1 (en) 2006-05-11
EP1812057A4 (en) 2009-07-22
JP2008518953A (ja) 2008-06-05

Similar Documents

Publication Publication Date Title
AU2023201579B2 (en) Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
TWI720448B (zh) 包含經共軛之莢膜糖抗原的致免疫性組成物、包含該致免疫性組成物之套組及彼等之用途
JP5555623B2 (ja) コンジュゲートワクチン用修飾多糖
AU2005302269B2 (en) Modified streptococcal polysaccharides and uses thereof
CN110859957A (zh) 包含缀合荚膜糖抗原的免疫原性组合物及其用途
JP2004346084A (ja) 複数種オリゴ糖の糖接合体型の細菌性髄膜炎ワクチン
US20230134033A1 (en) Immunogenic complex for eliciting protective immunity against group b streptococcus
US20160136285A1 (en) An isolated immunogenic bacterial antigen and its use in the prevention and treatment of infections caused by gram-negative bacteria
MXPA03010283A (es) Conjugados inmunogenicos de acido hialuronico de peso molecular bajo con toxinas de polipeptido.
MXPA05014015A (es) Vacunas contra grupo y nisseria meningitidis y combinaciones meningococales del mismo.
Lee Bacterial capsular polysaccharides: immunogenicity and vaccines
Jennings Chemically modified capsular polysaccharides as vaccines
JP2018522978A (ja) 免疫原性組成物
RU2818894C1 (ru) Свободные от примеси с-полисахарида капсульные полисахариды streptococcus pneumoniae с остатком 2,5-ангидроманнозы на восстанавливающем конце
Madoff et al. Surface structures of group B streptococci important in human immunity
WO2025193903A1 (en) Pneumococcal polysaccharide compositions and uses thereof
HK40042634A (en) Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
WESSELS et al. Group B Streptococcal Vaccines
HK1142261A (en) Modified polysaccharides for conjugate vaccines

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20080116